Christopher Veeck
@cveeck.bsky.social
31 followers 68 following 12 posts
28 | Post-Doctoral Researcher | Philipps University of Marburg | Stephan Becker Lab | Virology | Highly Pathogenic Viruses and Antiviral Therapy | Targeted Protein Degradation
Posts Media Videos Starter Packs
cveeck.bsky.social
I’m reminded how important it is to stay open-minded: proximity-induced modalities are still new to me in antivirals, but already well established in oncology – which made the discussions especially rewarding.

#DPhG2025
cveeck.bsky.social
As a molecular virologist, it’s humbling and inspiring to exchange ideas with experts in medicinal chemistry and drug development at the interface of chemistry and virology.

#DPhG2025
cveeck.bsky.social
Today I had the chance to speak at the Annual Meeting of the German Pharmaceutical Society in Freiburg about targeted protein degradation as a novel paradigm in antiviral therapy.

#DPhG2025
cveeck.bsky.social
This work proves that targeted protein degradation can go beyond enzymatic targets—opening up new viral proteins and ligands for therapeutic intervention. A promising step forward for antiviral PROTACs.
cveeck.bsky.social
We show that inactive ligands, binding outside of catalytic pockets, can still serve as potent warheads—expanding the antiviral degrader design space to new viral targets.
cveeck.bsky.social
Our lead compound, LLP019, robustly degraded Mpro in a cereblon-dependent manner and significantly reduced viral titers—despite its warhead being inactive as an inhibitor. Consequently, degradation, not inhibition, drove the antiviral effect.
cveeck.bsky.social
We redesigned pelitinib, an allosteric binder of SARS-CoV-2 Mpro, to create a series of degraders—leveraging its binding mode to go beyond conventional targeting of catalytic clefts.
cveeck.bsky.social
We asked: can ligands that bind outside—or in absence of—a catalytic cleft act as warheads for antiviral PROTACs? Until now, most such degraders targeted active sites. We set out to challenge that paradigm.
cveeck.bsky.social
Just dropped our new preprint on bioRxiv. I’m incredibly proud of this manuscript, which explores a novel application of PROTACs as antivirals. Many thanks to everyone who contributed to this exciting research!

www.biorxiv.org/content/10.1...

#preprint #PROTAC #TPD #Antiviral #OpenScience
Discovery of an Antiviral PROTAC Targeting the SARS-CoV-2 Main Protease Using an Allosteric Warhead
Targeted protein degradation represents a new paradigm in drug development. By hijacking the cellular ubiquitin-proteasome-system pathogenic proteins are degraded via heterobifunctional molecules, ref...
www.biorxiv.org
cveeck.bsky.social
While this marks the end of an important chapter in my life, I see it as the beginning of a new journey—one that I hope will lead me to exciting destinations, surrounded by inspiring mentors, colleagues, and friends in academia.
#PhDone #OneDegreeHotter
cveeck.bsky.social
A heartfelt thank you to everyone who has supported me throughout this journey. I am especially grateful to Prof. Becker, whose guidance made all of this possible in the first place, and to Dr. Anke Werner, who has been not only an incredible mentor but also a dear friend.
cveeck.bsky.social
Yesterday was a truly special day – I successfully defended my doctoral thesis at the Institute of Virology in Marburg! After years of education, hard work, research, and perseverance—combined with passion, joy, and, at times, tears and challenges—I am beyond grateful to have reached this milestone.